Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings

November 4, 2026 updated by: University of Southern Denmark

Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings. A Randomised Controlled Trial With a Qualitative Follow-up on Shared Decision-making in the Danish Mental Healthcare (the DAN-SHARE Study)

The DAN-SHARE study evaluates the use of DECISION HELPER™-based patient decision aids (PtDAs) in mental healthcare by exploring the impact of using a DECISION HELPER™ in-consult PtDA on patient involvement in decision-making. The study compares treatment consultations that use a PtDA with treatment consultations in which SDM is practiced without the use of a PtDA and hypothesises that the use of an in-consult PtDA will increase patient involvement in decision-making. Additionally, the study explores how patients and clinicians in mental healthcare understand and experience SDM and the use of the PtDA as part of the SDM practice in mental healthcare.

Study Overview

Detailed Description

Shared decision-making (SDM) is a collaborative model for treatment decision-making and is widely regarded as a cornerstone of patient-centered care. In SDM, patients and healthcare professionals jointly review available treatment options and identify the solution that best aligns with the patient's preferences and values. Patient decision aids (PtDAS) that are designed to support SDM by presenting treatment options and helping patients formulate and communicate their preferences, are often a central component of SDM. However, little is known about how healthcare professionals and patients understand and experience the use of patient decision aids in their clinical encounters. In particular, there is a lack of knowledge on the use of patient decision aids within mental healthcare.

This study aims to evaluate the impact of Decision Helper™-based PtDAs, when used in mental healthcare. Decision Helper™-based PtDAS are PtDAS designed by using a generic template known as the DECISION HELPER™. They are mandatory to develop and use as part of the implementation of SDM across all hospitals in the Region of Southern Denmark. However, there is a lack of knowledge of whether these PtDAs enhance SDM practices in psychiatric treatment consultations and supports people using mental health services in achieving greater involvement in treament decision-making.

In the study, patients are randomised to either an intervention group or an active control group. In the intervention group, treatment consultations are conducted using the Decision Helper™-based PtDA, whereas consultations in the control group follow SDM practices without the use of the PtDA. Additionally, the study explores patients' and mental healthcare professionals understanding and experiences the PtDAs as part of their SDM practice.

Study Type

Interventional

Enrollment (Estimated)

62

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • In treatment for a mental health disorder in one of the participating settings of the study

Exclusion Criteria:

  • Unable to understand Danish language
  • Unable to provide verbal and written informed consent
  • Diagnosed with cognitive impairment or dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SDM practice by using a Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

Active Comparator: SDM without the Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient involvement in decision-making
Time Frame: Throughout study completion, an average of 3 months.

Observed level of patient involvement in decision making according to the OPTION 12 scale.

OPTION 12 measures the level of patient involvement in decision-making by assessing recordings of treatment consultations on a 5-point Likert scale (0 to 4). Raw score rangs from 0 to 48 and is converted to a score ranging from 0 to 100. Higher scores indicate a higher level of patient involvement.

Throughout study completion, an average of 3 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-perceived level of involvement in decision-making
Time Frame: Patient-assessed within two weeks after the treatment consultation.

Patient-reported perceived involvement in decision-making, measured using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The SDM-Q-9 assesses the extent to which patients perceive themselves as being involved in decision-making. Patients rate their level of agreement with each of the 9 statements on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to a standardized score ranging from 0 to 100.

Patient-assessed within two weeks after the treatment consultation.
Clinician-perceived level of involving the patient
Time Frame: Clinician-assessed within two weeks after the treatment consultation.

Clinician-reported perceived level of patient involvement in decision-making, measured using the clinician version of the 9-item Shared Decision Making Questionnaire (SDM-Q-Doc). The SDM-Q-Doc assesses the extent to which clinicians perceive that they involve patients in the decision-making process. Clinicians evaluate each of the 9 items on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to scores ranging from 0 to 100. Higher scores indicate greater clinician-perceived involvement of patients in decision-making.

Clinician-assessed within two weeks after the treatment consultation.
Personal recovery
Time Frame: Patient-assessed within two weeks after the treatment consultation.

Patient-reported measure of personal recovery, assessed using the Brief INSPIRE-O. The Brief INSPIRE-O is a 5-item self-rated measure of recovery, i.e., a patient-reported outcome measure (PROM), that assesses personal recovery from the patient's perspective.

Each of the five statements is rated by the patient on a 5-point Likert scale ranging from 0 to 4. Item scores are summed and multiplied by 5 to generate a total score ranging from 0 to 100. Higher scores indicate higher levels of patient-perceived personal recovery.

Patient-assessed within two weeks after the treatment consultation.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

February 29, 2028

Study Registration Dates

First Submitted

May 1, 2026

First Submitted That Met QC Criteria

June 9, 2026

First Posted (Actual)

June 10, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe